EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

BCL2 drives castration resistance in castration-sensitive prostate cancer by orchestrating reciprocal crosstalk between oncogenic pathways

Rahim Hirani, Subhiksha Nandakumar, Nabila Zaman, Prathiksha Prabhakaraalva, Sarah Ann King, Teja Muralidhar Kalidindi, Romina Ghale, Sai Harisha Rajanala, Deborah C Fidele, Elisa De Stanchina, Gwo-Shu Mary Lee, Mary Ellen Taplin und 12 weitere

Cell Reports · 2025

DOI: 10.1016/j.celrep.2025.115779 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Reports, 2025. Verfasst von Rahim Hirani und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Proto-Oncogene Proteins c-bcl-2, Carcinogenesis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, U.S. Department of Defense, National Institutes of Health National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Progression following androgen-deprivation therapy (ADT) and the development of castration resistance is the leading cause of death among prostate cancer patients. Since there is currently a lack of known driver alterations associated with ADT resistance in castration-sensitive prostate cancer (CSPC), we investigated the critical role of crosstalk between cell signaling networks in early castration resistance. Our preclinical experiments and analyses of RNA sequencing data from clinical trials revealed nearly universal upregulation of BCL2 after ADT in CSPC cells. Mechanistically, our findings highlight a non-canonical function of BCL2 in orchestrating reciprocal signaling between the androgen receptor (AR)-BCL2 and phosphatidylinositol 3-kinase (PI3K) pathways, particularly upon ADT, potentially driving CSPC transformation into lethal castration-resistant prostate cancer (CRPC). Critically, our results provide a scientific rational that BCL2 inhibition should be trialed in CSPC in combination with ADT to impede or delay ADT-induced CSPC-to-CRPC transformation but may be ineffective if tested in patients who already have CRPC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantProto-Oncogene Proteins c-bcl-2CarcinogenesisMaleHumansSignal TransductionReceptors, AndrogenAnimalsCell Line, TumorMiceAndrogen AntagonistsGene Expression Regulation, NeoplasticPhosphatidylinositol 3-Kinases

Stichwörter der Autor:innen

ADTARBCL 2CP: CancerHedgehogPI3 kinase signalingcellular plasticitycombination therapyprostate cancersignalingvenetoclax

Substanzen

Proto-Oncogene Proteins c-bcl-2Receptors, AndrogenBCL2 protein, humanAndrogen AntagonistsPhosphatidylinositol 3-Kinases

Autor:innen und Institutionen

  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Departments of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Departments of Oncological Sciences Icahn School of Medicine at Mount Sinai, New York, NY, USA; Tisch Cancer Institute, Icahn School of…
  • Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Department of Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Förderung

  • NCI NIH HHS
  • U.S. Department of Defense
  • National Institutes of Health National Cancer Institute
  • Prostate Cancer Foundation
  • Icahn School of Medicine at Mount Sinai
  • National Institutes of Health

Zitieren

APA

Hirani, R., Nandakumar, S., Zaman, N., Prabhakaraalva, P., King, S. A., Kalidindi, T. M., Ghale, R., Rajanala, S. H., Fidele, D. C., De Stanchina, E., Mary Lee, G. S., Taplin, M. E., Balk, S. P., Sowalsky, A. G., Morris, M. J., Kishore Pillarsetty, N. V., Stopsack, K. H., Gopalan, A., Mucci, L. A., …, & Chakraborty, G. (2025). BCL2 drives castration resistance in castration-sensitive prostate cancer by orchestrating reciprocal crosstalk between oncogenic pathways. Cell Reports. https://doi.org/10.1016/j.celrep.2025.115779

Vancouver

Hirani R, Nandakumar S, Zaman N, Prabhakaraalva P, King SA, Kalidindi TM, et al. BCL2 drives castration resistance in castration-sensitive prostate cancer by orchestrating reciprocal crosstalk between oncogenic pathways. Cell Reports. 2025. doi:10.1016/j.celrep.2025.115779

BibTeX
@article{Hirani2025,
  author = {Hirani, Rahim and Nandakumar, Subhiksha and Zaman, Nabila and Prabhakaraalva, Prathiksha and King, Sarah Ann and Kalidindi, Teja Muralidhar and Ghale, Romina and Rajanala, Sai Harisha and Fidele, Deborah C and De Stanchina, Elisa and Mary Lee, Gwo-Shu and Taplin, Mary Ellen and Balk, Steven P and Sowalsky, Adam G and Morris, Michael J and Kishore Pillarsetty, Naga Vara and Stopsack, Konrad H and Gopalan, Anuradha and Mucci, Lorelei A and Kyprianou, Natasha and Tewari, Ashutosh K and Danila, Daniel and Kantoff, Philip W and Chakraborty, Goutam},
  title = {BCL2 drives castration resistance in castration-sensitive prostate cancer by orchestrating reciprocal crosstalk between oncogenic pathways},
  journal = {Cell Reports},
  year = {2025},
  doi = {10.1016/j.celrep.2025.115779}
}
Kostenlos starten →